Please login to the form below

Not currently logged in
Email:
Password:

Wyeth shareholders approve merger

Wyeth investors have voted to approve Pfizer's proposed $68bn takeover by an overwhelming 98 per cent, according to a preliminary tally

Wyeth investors have voted to approve Pfizer's proposed $68bn takeover by an overwhelming 98 per cent, according to a preliminary tally.

The news follows the recent announcement that the European Commission has approved the deal, subject to Pfizer's pledge to shed certain animal-health assets in Europe. The deal is still subject to clearance by anti-trust regulators in the US.

New York-based Pfizer expects the deal to close by the end of the year. 

21st July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics